Vertex Pharmaceuticals Statistics
Share Statistics
Vertex Pharmaceuticals has 257.53M shares outstanding. The number of shares has increased by -0.3% in one year.
| Shares Outstanding | 257.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 256.90M |
| Failed to Deliver (FTD) Shares | 61 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 3.51M, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 3.51M |
| Short % of Shares Out | 1.36% |
| Short % of Float | 1.37% |
| Short Ratio (days to cover) | 2.68 |
Valuation Ratios
The PE ratio is 28.97 and the forward PE ratio is 26.38. Vertex Pharmaceuticals's PEG ratio is 0.35.
| PE Ratio | 28.97 |
| Forward PE | 26.38 |
| PS Ratio | 10.62 |
| Forward PS | 8.2 |
| PB Ratio | 5.96 |
| P/FCF Ratio | 31.98 |
| PEG Ratio | 0.35 |
Enterprise Valuation
Vertex Pharmaceuticals has an Enterprise Value (EV) of 95.29B.
| EV / Earnings | 26.33 |
| EV / Sales | 9.66 |
| EV / EBITDA | 20.69 |
| EV / EBIT | 22.12 |
| EV / FCF | 29.06 |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.
| Current Ratio | 3.99 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 97.68 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on capital (ROIC) is 19.36%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 0.16% |
| Return on Capital (ROIC) | 19.36% |
| Revenue Per Employee | 1.83M |
| Profits Per Employee | 670.30K |
| Employee Count | 5.40K |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.71 |
Taxes
| Income Tax | 760.20M |
| Effective Tax Rate | 0.17 |
Stock Price Statistics
The stock price has increased by -6.05% in the last 52 weeks. The beta is 0.39, so Vertex Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -6.05% |
| 50-Day Moving Average | 450.59 |
| 200-Day Moving Average | 457.21 |
| Relative Strength Index (RSI) | 40.41 |
| Average Volume (20 Days) | 1.50M |
Income Statement
In the last 12 months, Vertex Pharmaceuticals had revenue of 9.87B and earned 3.62B in profits. Earnings per share was 14.05.
| Revenue | 9.87B |
| Gross Profit | 8.61B |
| Operating Income | 4.31B |
| Net Income | 3.62B |
| EBITDA | 4.61B |
| EBIT | 4.31B |
| Earnings Per Share (EPS) | 14.05 |
Balance Sheet
The company has 10.37B in cash and 808.40M in debt, giving a net cash position of 9.56B.
| Cash & Cash Equivalents | 10.37B |
| Total Debt | 808.40M |
| Net Cash | 9.56B |
| Retained Earnings | 10.14B |
| Total Assets | 22.24B |
| Working Capital | 5.83B |
Cash Flow
In the last 12 months, operating cash flow was 3.54B and capital expenditures -258.40M, giving a free cash flow of 3.28B.
| Operating Cash Flow | 3.54B |
| Capital Expenditures | -258.40M |
| Free Cash Flow | 3.28B |
| FCF Per Share | 12.72 |
Margins
Gross margin is 87.21%, with operating and profit margins of 43.65% and 36.68%.
| Gross Margin | 87.21% |
| Operating Margin | 43.65% |
| Pretax Margin | 44.38% |
| Profit Margin | 36.68% |
| EBITDA Margin | 46.66% |
| EBIT Margin | 43.65% |
| FCF Margin | 33.22% |
Dividends & Yields
VRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.42% |
| FCF Yield | 3.1% |
Analyst Forecast
The average price target for VRTX is $510, which is 24.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $510 |
| Price Target Difference | 24.1% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
Stock Splits
The last stock split was on Aug 24, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 24, 2000 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 10.78 |
| Piotroski F-Score | 1 |